氮卓斯汀联合孟鲁斯特钠治疗慢性荨麻疹44例临床观察

目的探讨氮卓斯汀联合孟鲁斯特钠治疗慢性荨麻疹的疗效和安全性。方法将入选的94例患者分为两组各47例。治疗组口服氮卓斯汀2mg,2次/d,同时口服孟鲁斯特钠0.1g,3次/d;对照组仅口服氮卓斯汀2mg,2次/d;两组连续服药8周,于治疗前和治疗后第2,4,8周及停药2个月后评定其疗效和安全性。结果治疗8周后,治疗组症状、体征总积分(1.72±1.47)明显低于治疗前(13.07±3.07);治疗组有效率(95.45%)明显高于对照组(74.42%);停药2个月后,治疗组复发率(16.13%)明显低于对照组(70.00%)。以上差异均有统计学意义(P均<0.05)。但治疗组不良反应发生率(12.77%)和对照组(10.64%)比较,差异无统计学意义(P>0.05)。结论氮卓斯汀联合孟鲁斯特钠治疗慢性荨麻疹疗效优于单用氮卓斯汀,不良反应轻微,并能降低停药后的复发率。

Therapeutic Effect of the Combination of Azelastine and Montelukast in Patients with Chronic Urticaria

Objective To assess therapeutic effect of combination treatment with azelastine and montelukast in patients with chronic urticaria. Methods Ninty-four patients with chronic urticaria were randomly allocated to treatment with oral azelastine 2mg (twice a day) or combination with oral montelukast 0.1g (three times a day) for 8 weeks. The efficacy and safety were evaluated before and after the 2th, 4th, 8th weeks after treatment. Results The symptoms and signs total score (1.72 ± 1.47) at 8 weeks was higher in the combination group compared with before treatment(13.07±3.07). The combination was more efficacious than azelastine alone, and the effective rate was 95.45% and 74.42% respectively. The recurrence rate was 16.13% in combination group and 70.00% in azelastine alone, there were significant difference between them(P all<0.05). The incidence rate of adverse reaction was 12.77% and 10.64%, there was not significant difference (P>0.05). Conclusion The therapeutic effect of combination with azelastine and montelukast is better in treatment of chronic urticaria compared with azelastine alone without significant adverse reaction, and a lower recurrence rate.